Therapeutic Effect of Imatinib Made in Real World to Newly Diagnosed Chronic Myeloid Leukemia.
10.19746/j.cnki.issn.1009-2137.2021.02.024
- Author:
Yu-Fan YE
1
,
2
;
Xiao-Ming LYU
3
;
Hai-Liang LI
4
Author Information
1. The First Clinical Medical College of Gannan Medical College
2. Ganzhou 341000，Jiangxi Province, China.
3. Department of Information,The First Affiliated Hospital of Gannan Medical University, Ganzhou 341000，Jiangxi Province, China.
4. Department of Hematology, The First Affiliated Hospital of Gannan Medical University, Ganzhou 341000，Jiangxi Province, China,E-mail: gyfylhl@163.com.
- Publication Type:Journal Article
- MeSH:
Antineoplastic Agents/therapeutic use*;
Benzamides/therapeutic use*;
China;
Fusion Proteins, bcr-abl/genetics*;
Humans;
Imatinib Mesylate/therapeutic use*;
Leukemia, Myelogenous, Chronic, BCR-ABL Positive/drug therapy*;
Piperazines;
Pyrimidines/therapeutic use*;
Treatment Outcome
- From:
Journal of Experimental Hematology
2021;29(2):456-461
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To evaluate the clinical efficacy and safety of domestic imatinib (made in China) in patients with newly diagnosed chronic myeloid leukemia chronic phase(CML-CP).
METHODS:Fifty-seven newly diagnosed CML-CP patients who did not receive any other anti-CML treatment were treated by domestic imatinib 400 mg once a day. The hematological, cytogenetic and molecular reactions and safety were observed and evaluated after 3, 6 and 12 months of treatment.
RESULTS:Fifty-six patients were treated for ≥3 and 6 months, among which 50 patients were treated for ≥12 months. After 3 months of treatment, 49 patients underwent hematological examination, 47 patients (95.9%) achieved complete hematological response (CHR), 49 patients underwent cytogenetic examination, 39 patients (79.6%) achieved major cytogenetic response (MCyR), and 12 patients (24.5%) achieved complete cytogenetic response (CCyR). 49 patients underwent the level of BCR-ABL test, including 41 patients (83.7%) with BCR-ABL
CONCLUSION:In the real world, Domestics imatinib mesylate is effective and safe in the treatment of newly diagnosed CML-CP patients, but long-term follow-up data are still necessary to verify its long-term efficacy.
